Best practices for integrating psychedelic medicines into psychotherapy
Empirical Evidence and Reliable Insights into a Promising, Emerging Practice
This comprehensive course offers mental health professionals the knowledge and skills to ethically integrate psychedelic harm reduction and integration therapies into their counseling practice. Grounded in current research and practice, this course explores the emerging field of psychedelic-assisted therapy.
Participants will examine the latest empirical evidence on psychedelic medicines in mental health treatment, with a focus on psilocybin, MDMA, and ketamine. The course covers key counseling techniques for preparation, intention setting, and integration, all within the framework of ethical guidelines and professional scope of practice.
Through expert instruction and practical examples, this course aims to equip counselors with cutting-edge knowledge and skills to enhance their professional practice and provide innovative, transformative care for their clients.
By the end of this course, you'll be able to:
Define key terminology related to psychedelic medicines, including mechanisms of action for psychedelics, entheogens, empathogens, and psychoplastogens.
Assess the benefits and risks of psilocybin, MDMA, and ketamine-assisted therapies.
Apply preparation, intention setting, and integration techniques to provide psychedelic harm reduction aligned with ethical guidelines and scope of practice.
Examine strategies to improve access, education, and service quality of psychedelic-assisted therapies for patients and clinicians.